Advances in Anaplastic Thyroid Cancer Treatment
Endocrinology and Metabolism Clinics of North America · 2025-09 · 54 (3) · 361-375
DOI: 10.1016/j.ecl.2025.03.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2025-09. Verfasst von Sarah Hamidi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
In 2025, it is no longer appropriate to view anaplastic thyroid cancer (ATC) patients with the sense of nihilism and hopelessness characteristic of the approach used in past decades. Early, rapid somatic genomic testing to determine BRAF (v-raf murine sarcoma viral oncogene homolog B1) status is critical for the optimal management of ATC. Surgical resection of the primary tumor after neoadjuvant approach, regardless of stage, should be the goal in most patients with BRAFV600E-mutated ATC to decrease locoregional complications, improve quality of life, and prolong survival. Combination therapy with kinase inhibitors plus immune checkpoint inhibitors is the preferred treatment regimen in patients with metastatic ATC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA.
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1445, Houston, TX 77030, USA.
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA. Electronic address: mcabani@mdanderson.org.
Förderung
- Merck
Zitieren
APA
Hamidi, S., Maniakas, A., & Cabanillas, M. E. (2025). Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America, 54(3), 361-375. https://doi.org/10.1016/j.ecl.2025.03.009
Vancouver
Hamidi S, Maniakas A, Cabanillas ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America. 2025;54(3):361-375. doi:10.1016/j.ecl.2025.03.009
BibTeX
@article{Hamidi2025,
author = {Hamidi, Sarah and Maniakas, Anastasios and Cabanillas, Maria E},
title = {Advances in Anaplastic Thyroid Cancer Treatment},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2025},
volume = {54},
number = {3},
pages = {361--375},
doi = {10.1016/j.ecl.2025.03.009}
}
EUVIMED